Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-06-26

FDA Approved: ZAVESCA — Supplemental Application (Actelion Pharmaceuticals US, Inc.)

View source ↗

Summary

FDA approved a supplemental application for ZAVESCA (miglustat) from Actelion Pharmaceuticals US, Inc., potentially updating the product label or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Zavesca (Miglustat)

Snippet

SUPPL AP for ZAVESCA (MIGLUSTAT)